Fosamax Osteonecrosis of the Jaw Attorney: Lawsuit Eligibility Overview

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Medication-Related Risks

For decades, general health and science information has served as a foundational resource for public understanding of medical conditions and treatment pathways. In the context of salivary gland health, this legacy has focused on common disorders such as infections, inflammatory conditions like Sjögren’s syndrome, and functional issues including drooling or dry mouth. These discussions have provided patients and professionals with a broad framework for recognizing symptoms and exploring interventions ranging from rehabilitation to surgical options. As this informational heritage evolves, attention increasingly turns to the intersection of systemic treatments and oral health. One area of growing concern involves the long-term effects of certain medications on jawbone integrity. Specifically, bisphosphonate therapies—widely prescribed for bone density management—have been associated with rare but serious complications in the oral cavity. This shift in focus moves the conversation from general salivary conditions toward a more targeted examination of medication-related risks. The transition from broad health education to occupational exposure concern becomes particularly relevant when considering how patients and professionals must now navigate potential adverse outcomes linked to pharmaceutical interventions. Understanding this progression is essential for evaluating individual circumstances and recognizing when specialized legal or medical guidance may be warranted.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health education, this section focuses specifically on Fosamax (alendronate), a bisphosphonate medication prescribed to treat osteoporosis and other bone conditions. A known but serious adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. This narrative reviews the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations for patients who may be evaluating legal options.

Clinical Presentation and Diagnosis of ONJ

Osteonecrosis of the jaw presents as exposed bone in the oral cavity that fails to heal within eight weeks after identification by a healthcare provider. The condition can occur spontaneously but is generally associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination and patient history. Imaging may be used to assess the extent of bone involvement. The condition can cause pain, swelling, and difficulty eating, and may require surgical intervention. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for osteoporosis, it can also impair the normal remodeling and repair of jawbone, particularly after dental procedures. The time to onset of ONJ symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The exact mechanism by which Fosamax contributes to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates accumulate in bone and suppress osteoclast activity, which can reduce the ability of the jawbone to remodel and repair microdamage. This is particularly problematic in the jaw, which undergoes constant mechanical stress from chewing and is frequently exposed to oral bacteria. The suppression of bone turnover may also impair the healing response after dental procedures, such as tooth extraction or implant placement. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and increasing the risk of necrosis. These mechanisms are supported by the observation that known risk factors for ONJ include invasive dental procedures, poor oral hygiene, and co-morbid disorders such as periodontal disease and infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Legal Considerations

The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also lists known risk factors, such as invasive dental procedures, cancer diagnosis, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical judgment of the treating physician and/or oral surgeon should guide the management plan based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who have developed ONJ after taking Fosamax may consider legal action if they believe the warnings were inadequate or if they were not properly informed of the risks. In evaluating eligibility for a lawsuit, key factors include the timeline between exposure and documented harm, the presence of known risk factors, and whether the patient received appropriate warnings from their healthcare provider. A study of specialists found that 56% of physicians had not encountered any cases of medication-related ONJ in the past year, while 44% had encountered between one and four cases (https://pubmed.ncbi.nlm.nih.gov/40604825/). The group that most frequently requested consultations regarding bisphosphonates was dentists (50.4%), followed by oral and maxillofacial surgeons (36.8%) (https://pubmed.ncbi.nlm.nih.gov/40604825/). When encountering patients with osteonecrosis, 39.2% of specialists most frequently referred them to oral and maxillofacial surgery (https://pubmed.ncbi.nlm.nih.gov/40604825/). These data suggest that awareness of ONJ varies among healthcare providers, which may be relevant in cases where a patient alleges that their doctor failed to warn them or to take appropriate preventive measures.

Timeline Between Exposure and Documented Harm

The onset of ONJ symptoms after starting Fosamax can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the condition may also develop after years of use, particularly if the patient undergoes dental procedures. The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients considering legal action, documenting the date of first Fosamax use, the date of any dental procedures, and the date of ONJ diagnosis is critical to establishing a causal link.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk is higher with longer use and after dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the symptoms of osteonecrosis of the jaw?

Symptoms include exposed bone in the mouth that does not heal within eight weeks, pain, swelling, infection, and difficulty eating. Diagnosis is clinical, often supported by imaging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long after taking Fosamax can ONJ develop?

ONJ symptoms can appear as early as one day to several months after starting Fosamax, but may also occur after years of use, especially following dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What factors increase the risk of ONJ in Fosamax users?

Risk factors include invasive dental procedures, poor oral hygiene, cancer, chemotherapy, corticosteroids, angiogenesis inhibitors, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Can I file a lawsuit if I developed ONJ after taking Fosamax?

You may be eligible if you believe the warnings were inadequate or you were not properly informed of the risks. Key factors include documented exposure, diagnosis, and timeline. Consult an attorney for personalized advice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.